According to ARRS’ American Journal of Roentgenology(AJR), adding diffusion-weighted MRI (DWI) to conventional MRI improves the differentiation of locally recurrent tumor and post-surgical fibrosis after pancreatic ductal adenocarcinoma (PDAC) resection, primarily due to improved sensitivity for recurrence.
“The findings indicate a potential role for MRI with DWI in surveillance protocols after PDAC resection,” clarified corresponding author Tae Wook Kang, MD from Samsung Medical Center in Seoul, South Korea.
Kang and colleagues’ retrospective study included 66 patients (35 men, 31 women; mean age, 60.5 years) with PDAC resection between January 2009 and March 2016, who underwent postoperative surveillance CT demonstrating a soft tissue lesion at the operative site or at the site of peripancreatic vessels and subsequent MRI with DWI for further evaluation.
CT at least 6 months after MRI served as reference standard, with increase in size of the soft tissue by ≥5 mm differentiating locally recurrent tumor (n=26) and post-surgical fibrosis (n=40).
Two observers independently reviewed MRI examinations in separate sessions: conventional MRI alone vs MRI with DWI.
Compared with MRI alone, MRI and DWI showed higher sensitivity (observer 1: 88.5% vs 61.5%, p=.008; observer 2: 84.6% vs 42.3%, p= .001) without difference in specificity (observer 1: 72.5% vs 80.0%, p=.08; observer 2, 95.0% vs 85.0%, p=.10) in detecting local recurrence after PDAC resection.
“MRI with DWI as a problem-solving tool during post-operative surveillance after PDAC resection could facilitate earlier detection of recurrences,” the authors of this AJR article added, “guiding prognostic assessment and treatment decisions.”
Source: American Roentgen Ray Society
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.